Compare
Impact Biomedical Inc. vs Jupiter Neurosciences, Inc. vs HCW Biologics Inc. vs Bioadaptives, Inc.
| Latest fiscal year | Impact Biomedical Inc. IBO | Jupiter Neurosciences, Inc. JUNS | HCW Biologics Inc. HCWB | Bioadaptives, Inc. BDPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $32.0K | $21.8K | $54.2K | $18.3K |
| Revenue growth (YoY) | n/a | n/a | -97.9% | +44.3% |
| Gross margin | n/m (computed) | 80.6% | 20.0% | 68.4% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$11.84M | -$8.64M | -$7.96M | -$1.56M |
| EPS (Diluted) | -$0.38 | -$0.25 | -$10.63 | -$0.15 |
| Operating cash flow | -$1.89M | -$5.41M | -$13.39M | -$516.0K |
| Free cash flow | n/a | n/a | -$13.39M | -$534.0K |
| Cash & equivalents | $3.0K | n/a | $1.95M | $215.2K |
| Total assets | $17.41M | $5.56M | $24.52M | $225.9K |
| Total liabilities | $1.85M | $7.40M | $21.76M | $2.36M |
| Shareholders' equity | $12.61M | -$1.83M | $2.76M | -$2.13M |
| Return on year-end equity | -93.9% | n/a | -287.9% | n/a |
| Shares outstanding | 104.62M | 34.45M | n/a | 12.01M |
Revenue, most recent five fiscal years
| Fiscal year | Impact Biomedical Inc. | Jupiter Neurosciences, Inc. | HCW Biologics Inc. | Bioadaptives, Inc. |
|---|---|---|---|---|
| Latest | $32.0K Ended 2025-12-31 | $21.8K Ended 2025-12-31 | $54.2K Ended 2025-12-31 | $18.3K Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $2.57M Ended 2024-12-31 | $12.7K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $2.84M Ended 2023-12-31 | $28.6K Ended 2023-12-31 |
| 3 years earlier | $50.0K Ended 2022-12-31 | n/a | $6.72M Ended 2022-12-31 | $17.2K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | $19.8K Ended 2021-12-31 |